Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.85+0.41 (+1.49%)
Close on Nov 17, 2026Market cap $4.83BP/E –Yield –
Cogent Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Cogent Biosciences's profit margin for the twelve months ending Dec 31, 2020 was -950.4%. For fiscal 2020 it was -950.4%, against -141.5% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | -950.4% | −808.9 |
| FY2019 | Dec 31, 2019 | -141.5% | +213.3 |
| FY2018 | Dec 31, 2018 | -354.8% | −49.8 |
| FY2017 | Dec 31, 2017 | -304.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | -16020.2% | −14851.3 |
| Q2 FY2020 | Jun 30, 2020 | -1400.2% | −1065.1 |
| Q1 FY2020 | Mar 31, 2020 | -86.7% | +296.3 |
| Q4 FY2019 | Dec 31, 2019 | 15.0% | +241.2 |
| Q3 FY2019 | Sep 30, 2019 | -1168.9% | −671.2 |
| Q2 FY2019 | Jun 30, 2019 | -335.1% | +206.5 |
| Q1 FY2019 | Mar 31, 2019 | -382.9% | −79.6 |
| Q4 FY2018 | Dec 31, 2018 | -226.2% | +88.9 |
| Q3 FY2018 | Sep 30, 2018 | -497.7% | −197.4 |
| Q2 FY2018 | Jun 30, 2018 | -541.6% | −259.6 |
| Q1 FY2018 | Mar 31, 2018 | -303.4% | +21.7 |
| Q4 FY2017 | Dec 31, 2017 | -315.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -300.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -282.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -325.1% | – |
See a number that looks wrong?